<DOC>
	<DOCNO>NCT02399592</DOCNO>
	<brief_summary>The purpose study investigate effect tocotrienol nutritional supplement combination bevacizumab patient advanced ovarian cancer .</brief_summary>
	<brief_title>Tocotrienol Nutritional Supplement Patients With Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<criteria>Histologically confirm epithelial , primary fallopian primary peritoneal cancer . Prior treatment least two different cytostatic regimen include platinum . Progression previous treatment . Measurable disease RECIST 1.1 evaluable GCIG CA125 criterion . Age ≥ 18 year . Performance stage 02 . Adequate bone marrow function , liver function , renal function ( within 7 day prior inclusion ) : WBC ≥ 3.0 * 10^9/l neutrophil ( ANC ) ≥ 1.5 * 109/l Platelet count ≥ 100 * 10^9/l Hemoglobin ≥ 6 mmol/l Serum bilirubin &lt; 2.0 * ULN Serum transaminase ≤ 2.5 * ULN Serum creatinine ≤ 1.5 ULN Urine dipstick protein &lt; 2+ . If dipstick show protein ≥2+ 24 hour urine testing must make protein content &lt; 1 g. Written inform consent . Other malignant disease within 5 year prior inclusion study , except curatively treat basal cell squamous cell carcinoma skin type cancer minimal risk recurrence . Other experimental therapy participation another clinical trial within 28 day prior treatment initiation . Underlying medical disease adequately treat ( diabetes , cardiac disease ) . Uncontrolled hypertension ( BT &gt; 150/100 despite antihypertensive treatment ) . Surgery , incl . open biopsy , within 4 week prior first dose bevacizumab . Nonhealing wounds fracture . Cerebral vascular attack , transient ischemic attack subarachnoidal hemorhage within 6 month start treatment . Clinically significant cardiovascular disease , include : Myocardial infarction unstable angina within 6 month start treatment New York heart Association ( NYHA ) class ≥ 2 Poorly control cardiac arrhythmia despite medication Periferal vascular disease grade ≥ 3 Allergy active substance auxiliary agent Bleeding tumor Pregnant breastfeeding patient . For fertile woman negative pregnancy test screen mandatory . Fertile patient willing use effective method contraception treatment 6 month end treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Platinum resistant</keyword>
</DOC>